Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer

NCT01032291 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT01032291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01032291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2009
Completion date
January 31, 2011
Enrollment
51 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer